Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Tempol by Matrix Biomed for Glioblastoma Multiforme (GBM): Likelihood of Approval
Tempol is under clinical development by Matrix Biomed and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...